Naik, Swati
Li, Ying
Talleur, Aimee C.
Selukar, Subodh
Ashcraft, Emily
Cheng, Cheng
Madden, Renee M.
Mamcarz, Ewelina
Qudeimat, Amr
Sharma, Akshay
Srinivasan, Ashok
Suliman, Ali Y.
Epperly, Rebecca
Obeng, Esther A.
Velasquez, M. Paulina
Langfitt, Deanna
Schell, Sarah
Métais, Jean-Yves
Arnold, Paula Y.
Hijano, Diego R.
Maron, Gabriela
Merchant, Thomas E.
Akel, Salem
Leung, Wing
Gottschalk, Stephen
Triplett, Brandon M.
Funding for this research was provided by:
American Lebanese Syrian Associated Charities
Article History
Received: 6 May 2024
Accepted: 13 June 2024
First Online: 27 June 2024
Declarations
:
: Written informed consent was obtained in accordance with the Declaration of Helsinki. The study was approved by St. Jude’s Institutional Review Board and Investigational Device Exemption for the use of the CliniMACS Plus device (Miltenyi Biotec) was granted by the Food and Drug Administration.
: N/A.
: ASh has received consultant fees from Spotlight Therapeutics, Medexus Inc., Vertex Pharmaceuticals, Sangamo Therapeutics and Editas Medicine, honoraria from Vindico Medical Education, research funding from CRISPR Therapeutics, and is a medical monitor for the RCI BMT CSIDE clinical trial. SSe has received research funding from Jazz Pharmaceuticals. MPV is co-inventor on patent applications in cell therapy and a member of the Rally! Foundation Medical Advisory Board. DRH receives research support from Merck. GM conducts sponsored research for Astellas Inc and SymBio Pharmaceutical. SG is a co-inventor on patent applications in the fields of cell or gene therapy for cancer, a member of the Scientific Advisory Board of Be Biopharma and CARGO, and the Data and Safety Monitoring Board (DSMB) of Immatics and has received honoraria from TESSA Therapeutics within the last year. BMT has received travel support from Miltenyi Biotech to present published data. The remaining authors declare no competing interests.